Regulatory Requirements, Cost Contributing to Decline of U.S. Medical Device Startups, Survey Finds
A survey of medical technology companies and venture capital firms with a presence in the life sciences field revealed that the U.S. is at risk of losing its global leadership position in medtech innovation because of unpredictable, inefficient, and expensive regulatory processes within the Food and Drug Administration (FDA). Further, survey data indicate that innovators and medical device companies are relocating to other countries in greater numbers to take advantage of more streamlined regulatory processes and lower costs.